Expanded Access Policy for Investigational Medicines

An investigational product is a drug product that has not been approved by FDA. Expanded access refers to the use of an investigational product outside of a clinical trial in the setting of a serious and life-threatening illness where there are no other treatment options, potential patient benefit justifies the potential risks of treatment, and providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.

Spero’s Expanded Access Policy:

Spero Therapeutics is committed to advancing novel treatment approaches for bacterial infections. Further, Spero is dedicated to delivering differentiated medicines to help patients suffering from serious rare diseases and MDR bacterial infections.

As part of that commitment, Spero conducts clinical trials of our investigational medicines to evaluate their safety and effectiveness for our patients. The data generated from these clinical trials are used to obtain regulatory approval of our medicines, and it is the most fair and efficient means of making them available to those in need. Therefore, the company’s position is that enrollment in a Spero-sponsored clinical trial is the preferred route of access to our investigational drug candidates. Clinical trials ensure rigorous evaluation and oversight of all patients involved. Information about ongoing clinical trials is posted at:


None of Spero’s investigational drug products are available for expanded access at this time.

Patients should consult with their healthcare professional if they are interested in learning if enrolling in a clinical trial is an option for them. Patients and caregivers can also learn more about clinical trials here:


For additional information about Spero’s clinical trials, please contact: expandedaccess@sperotherapeutics.com

Spero’s Expanded Access policy is subject to change at Spero’s sole discretion. Updates to the policy will be posted here.